Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology [Yahoo! Finance]
Vir Biotechnology (NASDAQ:VIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program [Yahoo! Finance]
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.